We found that in BLCA, COL5A1 expression had a negative correlation between the IC50 of cisplatin, while having a positive relationship with the IC50 of gemcitabine (Figures 16(b) and 16(c)). This evidence concerns the gene COL5A1 and bladder transitional cell carcinoma.